Knowledge Base

Back to home

Knowledge Base

HIV / AIDS

HIV / AIDS

Information in relation to HIV/AIDS including our clinical trial.

HIV Clinical Trial

Do patients who underwent leukapheresis before receiving a COVID vaccine need a COVID booster after they are re-infused with modified CD4 cells that have not been exposed to the vaccine?

Will the HIV AGT103-T Phase 1 study results be released?

Do you recruit or consider overseas participants for AGT103-T clinical trials?

Why is the FDA taking so long?

We are not from the US, can we be registered for this test?

How long will each of the 3 FDA trials take?

Will the Clinical Trials take more or less than 10 years?

How can I see updates on the status of the HIV Phase 1 trial?

How can people outside the US participate in the trials?

When will the Phase 1 clinical trial start?

When will AGT release clinical trial results?

Can I volunteer to be a participant in the Phase 1 clinical trial?

When will AGT start a clinical trial outside the United States?

How can I enroll in the clinical trial of AGT’s Phase 1 HIV therapy?

What is the status of the Clinical Trial?

See more

General HIV Topic

Is there medicine to treat HIV?

There is still a lot of skepticism about this technology, can you explain it more carefully?

Can AGT give me advice on my diagnosis?

HIV Clinical Trial Site Information

Specific Patient information regarding participating in Clinical Trials

Can I participate in the trials despite being in a different part of the country?

Will the Clinical Trials take more or less than 10 years?

Cost of Treatment

How much will AGT103-T cost?

Treatment Availability

When will AGT103-T be available for use?

Is it possible to access AGT's treatment outside of the US?

AGT103-T Functionality

Does AGT103-T remove HIV from the CD4 cells’ DNA so that those transplanted cells will not becomes sources of viral replication when ARV therapy ends, leading to those cells’ death?

Was there any actual ex-vivo evidence from AGT’s or NIH/Dr. Chun’s ex vivo lab work that suggested latently infected cells were destroyed or viral release from latently infected inhibited?

If the product inhibits release of virus from the cells by destabilizing virus RNA so that the cells cannot produce virus, why introduce genes to protect the outer wall of the cell at the CCR5 site?

If one of the intentions of AGT103-T is to inhibit replication in latently infected cells, are you hoping for a functional cure but not expecting a sterilizing cure that eliminates all infected cells?

If the study product does not make modifications to CXCR4 for safety reasons, then will this product not work on someone whose trofile comes back as CXCR4-type HIV?

I believe I read that AGT believes if the product works as a cure in some capacity, it would do so within 11-12 days. What was the evidentiary basis for that timeframe? Something seen ex-vivo?

Will AGT103-T work?

Does the cure for HIV work yet?

See more